Drugs / CD200AR-L
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06305910 | Mar 2024 → Sep 2025 overdue | diffuse midline glioma, H3 K27M-mutant | OX2 Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD200AR-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06305910 ↗ |
| Route | Other | “2 supraclavicular injections of CD200AR-L each day” NCT06305910 ↗ |